Healthcare - Biotechnology - NASDAQ - US
$ 7.74
-8.73 %
$ 475 M
Market Cap
-3.49
P/E
INCOME STATEMENT
0
REVENUE
-143 M
OPERATING INCOME
-135 M
NET INCOME
EFFICIENCY
Earnings Waterfall
Monte Rosa Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 6.22 M |
| Gross Profit | -6.22 M |
| Operating Expenses | 143 M |
| Operating Income | -143 M |
| Other Expenses | -7.96 M |
| Net Income | -135 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| REVENUE | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||
| Cost Of Revenue | 6.2 | 8.6 | 2.1 | 0.5 | 72 K |
| Gross Profit | (6.2) | (8.6) | (2.1) | (0.5) | 72 K |
| OPERATING INCOME | |||||
| Operating Expenses | 143.3 | 112.4 | 72.9 | 28.0 | 8.0 |
| Selling, General and Administrative Expenses | 32.0 | 27.3 | 15.7 | 4.0 | 0.6 |
| Research and Development Expenses | 111.3 | 85.1 | 57.2 | 24.0 | 7.3 |
| Operating Income | (143.3) | (112.4) | (72.9) | (28.0) | (8.0) |
| PRE-TAX INCOME | |||||
| Interest Income Expense | 0 | 3.8 | 0 | 0 | 1 K |
| Total Other Income | 8.3 | 3.9 | (1.1) | (7.9) | 0.3 |
| Pre-Tax Income | (135.0) | (108.5) | (74.0) | (35.9) | (7.7) |
| NET INCOME | |||||
| Tax Provision | 0.3 | (3.9) | (2.0) | 0.2 | 0.3 |
| Net Income | (135.4) | (104.6) | (71.9) | (36.1) | (8.0) |
| EPS | 2.63 | 2.22 | 1.55 | 0.82 | 0.18 |